Abiopharma

🔍 Jashnani Yogesh (Director)

Company: Airsculpt Technologies, Inc. (AIRS)

Report Date: 2025-10-27

Detailed Transactions and Holdings:

• Acquired 56,097 shares of Common Stock, $0.001 Par Value (Direct)
  Date: 2025-10-27 | Code: M | equity_swap_involved: 0 | shares_owned_after: 520,976.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 56,097 shares of Performance Stock Units (Derivative)
  Date: 2025-10-27 | Code: M | Expires: 2028-01-07 | equity_swap_involved: 0 | shares_owned_after: 164,289.00 | transaction_form_type: 4 | Footnotes: F1, F1

Footnotes:

• F1: As previously reported, the Reporting Person was granted an award of 220,386 Performance Stock Units ("PSUs") on January 7, 2025 pursuant to the Company's 2021 Equity Incentive Plan. Each PSU represented a contingent right to receive one share of common stock, $0.001 par value per share ("Common Stock"), of the Issuer, vesting proportionally based on the achievement of four different stock price performance goals. On October 27, 2025, the first of the four stock price performance goals set forth in the PSU award was met upon the Common Stock achieving a 60-day average price equal or greater than $7.56 per share, resulting in the vesting of 56,097 shares of Common Stock underlying 56,097 PSUs.